The four TCGA molecular profiles (e.g., POLE-mutated, p53-abnormal) have evolved beyond predicting outcomes to actively guiding treatment, such as de-escalating therapy for low-risk groups and escalating for high-risk ones.

Clinicians must be cautious when interpreting genomic reports. A 'negative' result doesn't confirm the absence of a mutation; it only means the specific test, with its inherent limitations like an inability to detect copy number alterations, did not identify it. This distinction is critical for accurate diagnosis.

Experts believe molecular tests like Decipher and PTEN status are superior to simply counting bone lesions for guiding treatment. While not yet standard practice for all decisions, this represents a significant shift towards using underlying tumor biology to determine therapy, like adding docetaxel.

Advanced imaging techniques can provide clues about a glioma's molecular subtype before surgery. Specifically, a 'T2-FLAIR mismatch' finding on an MRI is highly indicative of an IDH-mutant astrocytoma, allowing clinicians to anticipate the tumor's molecular profile and plan treatment strategies earlier.

Glioblastoma isn't a single mass but has finger-like 'tentacles' (diffuse infiltration) extending into brain tissue. It is also genetically and cellularly diverse, meaning a single-pathway drug will inevitably miss many tumor cells, leading to rapid recurrence and treatment failure.

Unlike most cancers, National Comprehensive Cancer Network (NCCN) guidelines recommend clinical trials as the preferred first-line treatment for glioblastoma patients with good performance status. This rare recommendation highlights the dismal outcomes with existing therapies and the urgent need for therapeutic innovation.

In low-grade gliomas, FET PET can pinpoint metabolically active regions within larger, non-specific areas of flare signal abnormality. This helps neurosurgeons target biopsies or resections to the most aggressive parts of the tumor, potentially identifying transformation to a higher grade.

The intensity and volume of FET PET activity serve as a powerful prognostic marker in glioma patients. Even when imaging suggests treatment-related changes rather than active tumor, elevated PET signals still correlate with a worse overall outcome, providing an additional layer of risk stratification.

Different commercial and institutional molecular testing platforms can produce disparate results for the same tumor specimen. This variability in tests for markers like MGMT promoter methylation or 1p19q codeletion can lead to incorrect diagnoses and misguided treatment plans for glioma patients.